Claims
- 1. (Original) A pharmaceutical composition comprising an agent effective to elicit an immunogenic response to alpha-synuclein and an adjuvant.
- 2. (Original) The pharmaceutical composition of claim 1, wherein the agent is alpha-synuclein or an immunogenic fragment thereof.
- 3. (Original) The pharmaceutical composition of claim 2, wherein the agent is alpha-synuclein.
- 4. (Original) The pharmaceutical composition of claim 2, wherein the agent is immunogenic alpha-synuclein fragment.
- 5. (Original) The pharmaceutical composition of claim 4, wherein the agent is NAC.
- 6. (Original) The pharmaceutical composition of any one of claims 1-5, wherein the agent is linked to a carrier molecule to form a conjugate.
- 7. (Original) The pharmaceutical composition of any one of claims 1-5, further comprising a pharmaceutically acceptable adjuvant.
- 8. (Original) The pharmaceutical composition of claim 7, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, alum and Freund's adjuvant.
- 9. (Original) A pharmaceutical composition comprising an agent effective to elicit an immunogenic response against an alpha-synuclein component of an amyloid plaque in a patient.
- 10. (Original) The pharmaceutical composition of claim 9, wherein the agent is alpha-synuclein or an immunogenic alpha-synuclein fragment.
- 11. (Original) The pharmaceutical composition of claim 9, wherein the agent is alpha-synuclein.
- 12. (Original) The pharmaceutical composition of claim 9, wherein the agent is an immunogenic alpha-synuclein fragment.
- 13. (Original) The pharmaceutical composition of claim 12, wherein the immunogenic alpha-synuclein fragment is NAC.
- 14. (Original) The pharmaceutical composition of claim 9, wherein the agent is an antibody or fragment thereof specifically binds or an alpha-synuclein component of an amyloid plaque.
- 15. (Original) A pharmaceutical composition comprising an antibody that specifically binds alpha-synuclein or a fragment thereof and a pharmaceutically acceptable carrier.
- 16. (Original) The pharmaceutical composition of claim 15, wherein the antibody specifically binds alpha-synuclein.
- 17. (Original) The pharmaceutical composition of claim 15, wherein the antibody specifically binds an alpha-synuclein fragment.
- 18. (Original) The pharmaceutical composition claim 15, wherein the antibody is a humanized antibody.
- 19. (Original) The pharmaceutical composition claim 15, wherein the antibody is human.
- 20. (Original) The pharmaceutical composition claim 18 or 19, wherein the antibody is an antibody of human IgG1 isotype.
- 21. (Original) The pharmaceutical composition claim 15, wherein the antibody is a monoclonal antibody.
- 22. (Original) The pharmaceutical composition of claims 15, wherein the antibody is a polyclonal antibody.
- 23. (Original) The pharmaceutical composition claim 15, wherein the antibody is prepared from a human immunized with alpha-synuclein peptide.
- 24. (Original) A pharmaceutical composition for preventing or treating a disease characterized by an amyloid deposit in a patient, comprising an effective dosage of an antibody or antibody fragment that specifically binds to an amyloid component present in said deposit, wherein the amyloid component is a alpha-synuclein or a fragment thereof.
- 25. (Original) The pharmaceutical composition of claim 24, wherein the synuclein fragment is NAC.
- 26. (Original) The pharmaceutical composition of claim 25, wherein the antibody specifically binds to a synuclein fragment without binding to alpha-synuclein (SEQ ID NO: 1).
- 27. (Original) The pharmaceutical composition of claim 24, wherein said effective dosage is characterized by an amount of antibody or antibody fragment effective to produce a level in the patient serum of immunoreactivity against the amyloid component that is at least about four times higher than a serum level of immunoreactivity against the component measured in a pre-treatment control serum sample.
- 28. (Original) The pharmaceutical composition of claim 24, wherein the pharmaceutical composition includes a carrier.
- 29. (Original) The pharmaceutical composition of claim 24, wherein the pharmaceutical composition is formulated for administration intraperitoneally, orally, subcutaneously, intramuscularly, intranasally, topically or intravenously.
- 30. (Original) The pharmaceutical composition of claim 24, wherein said pharmaceutical composition is formulated as a sustained release composition.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Application No. 60/423,012, filed Nov. 1, 2002. This application is also a continuation-in-part of U.S. application Ser. No. 09/585,817, filed Jun. 1, 2000, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Application No. 60/137,010, filed Jun. 1, 1999. This application is also a continuation-in-part of U.S. application Ser. No. 09/580,015, filed May 26, 2000. The foregoing applications are incorporated by reference herein for all purposes.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60423012 |
Nov 2002 |
US |
|
60137010 |
Jun 1999 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09585817 |
Jun 2000 |
US |
Child |
10698099 |
Oct 2003 |
US |
Parent |
09580015 |
May 2000 |
US |
Child |
10698099 |
Oct 2003 |
US |